Atossa Genetics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Seattle WA United States (2009)

Organization Overview

First Clinical Trial
2016
NCT02540330
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Atossa Genetics, Inc. | Atossa Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

endoxifen (3 trials)

exemestane (aromasin) (1 trial)

fulvestrant (faslodex) (1 trial)

goserelin (zoladex) (1 trial)

Drugs in Phase 1 Trials (1)

at-301 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Ductal (Phase 2)

Carcinoma in Situ (Phase 2)

Carcinoma, Intraductal, Noninfiltrating (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5